Outcomes in post–allo-HCT relapsed CLL patients treated with ibrutinib. (A) Lymph node response for 15 patients shown as the percent change from baseline, measured by the sum of the products of the lymph node diameters (SPD). One patient was not evaluable for response. Median percent reduction was 88.6%. (B) Investigator-assessed response rates. One patient with a del17p chromosomal abnormality was not evaluable for response. No patients on the study showed disease progression as best response; 1 patient in each group did not have a postbaseline response assessment. (C) Kaplan-Meier curve showing progression-free survival of 77% at 24 months postibrutinib initiation. (D) The most common treatment-emergent AEs (occurring in ≥15% of patients) are shown for this cohort of patients treated as part of the multi-institutional clinical trials. CR, complete response; PR, partial response; PR-L, partial response with lymphocytosis; SD, stable disease.